Argos Therapeutics Appoints Robert F. Carey To Board
This article was originally published in Scrip
Robert F. Carey, who is currently executive vice-president and chief business officer for Horizon Pharma Plc., has been named to Argos Therapeutics' board of directors. Carey has over 30 years' experience in healthcare investment banking, business development and investor relations and was also responsible for initiating and managing JMP Securities' healthcare group.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.